These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 31979216)

  • 1. Differential Dependency of Human Pancreatic Cancer Cells on Targeting PTEN via PLK 1 Expression.
    Lee J; Lee J; Sim W; Kim JH
    Cancers (Basel); 2020 Jan; 12(2):. PubMed ID: 31979216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Silencing of polo-like kinase (Plk) 1 via siRNA causes induction of apoptosis and impairment of mitosis machinery in human prostate cancer cells: implications for the treatment of prostate cancer.
    Reagan-Shaw S; Ahmad N
    FASEB J; 2005 Apr; 19(6):611-3. PubMed ID: 15661849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical and prognostic value of polo-like kinase 1 in lung squamous cell carcinoma patients: immunohistochemical analysis.
    Li H; Wang H; Sun Z; Guo Q; Shi H; Jia Y
    Biosci Rep; 2017 Aug; 37(4):. PubMed ID: 28724602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of Matrix Metalloproteinase 11 as a Prognostic Biomarker in Pancreatic Cancer.
    Lee J; Lee J; Kim JH
    Anticancer Res; 2019 Nov; 39(11):5963-5971. PubMed ID: 31704821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PDZ-containing 1 acts as a suppressor of pancreatic cancer by regulating PTEN phosphorylation.
    Ma Q; Wu X; Wu J; Wu H; Xiao Y; Wang L; Liang Z; Liu T
    Oncotarget; 2017 Sep; 8(42):72893-72909. PubMed ID: 29069834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of Polo-like kinase 1 is a common and early event in pancreatic cancer.
    Weichert W; Schmidt M; Jacob J; Gekeler V; Langrehr J; Neuhaus P; Bahra M; Denkert C; Dietel M; Kristiansen G
    Pancreatology; 2005; 5(2-3):259-65. PubMed ID: 15855824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polo-like kinase (Plk) 1: a novel target for the treatment of prostate cancer.
    Ahmad N
    FASEB J; 2004 Jan; 18(1):5-7. PubMed ID: 14718382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thoughts on the current assessment of Polo-like kinase inhibitor drug discovery.
    Strebhardt K; Becker S; Matthess Y
    Expert Opin Drug Discov; 2015 Jan; 10(1):1-8. PubMed ID: 25263688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of miR
    Liu Y; Hu Q; Ao J; Li H; Li M
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2020 Mar; 45(3):280-289. PubMed ID: 32386020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of cell apoptosis and proliferation in pancreatic cancer through PI3K/Akt pathway via Polo-like kinase 1.
    Mao Y; Xi L; Li Q; Cai Z; Lai Y; Zhang X; Yu C
    Oncol Rep; 2016 Jul; 36(1):49-56. PubMed ID: 27220401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation between protein expression of PTEN in human pancreatic cancer and the proliferation, infiltration, metastasis and prognosis.
    Tao J; Xiong J; Li T; Yang Z; Li X; Li K; Wu H; Wang C
    J Huazhong Univ Sci Technolog Med Sci; 2006; 26(4):444-7. PubMed ID: 17120744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of polo-like kinases in retinoblastoma: correlation with patient outcome, clinical and histopathological parameters.
    Singh L; Pushker N; Sen S; Singh MK; Chauhan FA; Kashyap S
    Clin Exp Ophthalmol; 2015 Aug; 43(6):550-7. PubMed ID: 25754767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The E3 ubiquitin ligase NEDD4 is translationally upregulated and facilitates pancreatic cancer.
    Weng M; Luo ZL; Wu XL; Zeng WZ
    Oncotarget; 2017 Mar; 8(12):20288-20296. PubMed ID: 28423617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting Polo-Like Kinases: A Promising Therapeutic Approach for Cancer Treatment.
    Liu X
    Transl Oncol; 2015 Jun; 8(3):185-95. PubMed ID: 26055176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CBX7 suppresses cell proliferation, migration, and invasion through the inhibition of PTEN/Akt signaling in pancreatic cancer.
    Ni S; Wang H; Zhu X; Wan C; Xu J; Lu C; Xiao L; He J; Jiang C; Wang W; He Z
    Oncotarget; 2017 Jan; 8(5):8010-8021. PubMed ID: 28030829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MiR-132 promotes the proliferation, invasion and migration of human pancreatic carcinoma by inhibition of the tumor suppressor gene PTEN.
    Zhang H; Liu A; Feng X; Tian L; Bo W; Wang H; Hu Y
    Prog Biophys Mol Biol; 2019 Nov; 148():65-72. PubMed ID: 28941804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA-92a promotes epithelial-mesenchymal transition through activation of PTEN/PI3K/AKT signaling pathway in non-small cell lung cancer metastasis.
    Lu C; Shan Z; Hong J; Yang L
    Int J Oncol; 2017 Jul; 51(1):235-244. PubMed ID: 28534966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential regulation of polo-like kinase 1, 2, 3, and 4 gene expression in mammalian cells and tissues.
    Winkles JA; Alberts GF
    Oncogene; 2005 Jan; 24(2):260-6. PubMed ID: 15640841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PLK-1 Expression is Associated with Histopathological Response to Neoadjuvant Therapy of Hepatic Metastasis of Colorectal Carcinoma.
    Fernández-Aceñero MJ; Cortés D; Gómez del Pulgar T; Cebrián A; Estrada L; Martínez-Useros J; Celdrán A; García-Foncillas J; Pastor C
    Pathol Oncol Res; 2016 Apr; 22(2):377-83. PubMed ID: 26577686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analyses of expressions and prognostic values of Polo-like kinases in non-small cell lung cancer.
    Zeng Y; Li N; Liu W; Zeng M; Cheng J; Huang J
    J Cancer Res Clin Oncol; 2020 Oct; 146(10):2447-2460. PubMed ID: 32627077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.